The pharmaceutical industry is a key partner in Europe’s fight against disease, developing new treatments and cures for patients across Europe. It is imperative that Europe remains a competitive destination for medical research and development by maintaining, sustaining and developing a predictable, robust regulatory and innovation-supportive incentives environment.

In 2020, China became the main trading partner of Germany and the EU. The German economy is the strongest in Europe, and China is the driver of global economic growth. Therefore, the ties between Germany and China are of particular importance for the development of the Eurasian railway route.